HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients

SF Chen, YC Shen, CH Chen - Psychopharmacology, 2009 - Springer
Rationale Aripiprazole acts as a partial agonist at dopamine D2 and D3 and serotonin 1A
receptors and as an antagonist at serotonin 2A receptors (HTR2A). Since aripiprazole acts …
被引用次数：68 相关文章

HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients

SF Chen, YC Shen, CH Chen - Psychopharmacology, 2009 - infona.pl
Rationale Aripiprazole acts as a partial agonist at dopamine D2 and D3 and serotonin 1A
receptors and as an antagonist at serotonin 2A receptors (HTR2A). Since aripiprazole acts …

HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients

SF Chen, YC Shen, CH Chen - Psychopharmacology, 2009 - tcu.elsevierpure.com
摘要Rationale: Aripiprazole acts as a partial agonist at dopamine D2 and D3 and serotonin
1A receptors and as an antagonist at serotonin 2A receptors (HTR2A). Since aripiprazole …

HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients

SF Chen, YC Shen, CH Chen - Psychopharmacology, 2009 - pubmed.ncbi.nlm.nih.gov
Rationale Aripiprazole acts as a partial agonist at dopamine D2 and D3 and serotonin 1A
receptors and as an antagonist at serotonin 2A receptors (HTR2A). Since aripiprazole acts …

HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients.

SF Chen, YC Shen, CH Chen - Psychopharmacology, 2009 - search.ebscohost.com
Aripiprazole acts as a partial agonist at dopamine D2 and D3 and serotonin 1A receptors
and as an antagonist at serotonin 2A receptors (HTR2A). Since aripiprazole acts as an …

HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients

S Chen, Y Shen, C Chen - Psychopharmacology, 2009 - search.proquest.com
Aripiprazole acts as a partial agonist at dopamine D2 and D3 and serotonin 1A receptors
and as an antagonist at serotonin 2A receptors (HTR2A). Since aripiprazole acts as an …

[引用][C] HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients

SF CHEN, YC SHEN, CH CHEN - Psychopharmacologia, 2009 - pascal-francis.inist.fr
HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon
aripiprazole treatment in schizophrenic patients CNRS Inist Pascal-Francis CNRS Pascal …

HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients.

SF Chen, YC Shen, CH Chen - Psychopharmacology, 2009 - europepmc.org
Objectives This study investigated whether the efficacy of aripiprazole can be predicted by
functional HTR2A A-1438G/T102C polymorphisms (rs63311/rs6313) as modified by clinical …

HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients.

SF Chen, YC Shen, CH Chen - Psychopharmacology, 2009 - search.ebscohost.com
Aripiprazole acts as a partial agonist at dopamine D2 and D3 and serotonin 1A receptors
and as an antagonist at serotonin 2A receptors (HTR2A). Since aripiprazole acts as an …

[引用][C] HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients

SF CHEN, YC SHEN, CH CHEN - Psychopharmacologia, 2009 - Springer